Macrogen established its headquarters in the U.S. in Maryland in 2004 as Macrogen Corp. In that year, it partnered with Applied Biosystems for a DNA chip project, and launched a new Sanger sequencing service. The global brand Macrogen continued to expand into Japan and European countries as the U.S. branch grew locally. In 2010, Macrogen Corp. created Axeq Technologies, which served as a sales and marketing function for Next Generation Sequencing.
Macrogen Corp. opened a New York office in 2011, and a Massachusetts office the following year. In 2012, it established the Macrogen Clinical Laboratory. It also became CLIA-certified for whole exome sequencing (WES) and whole genome sequencing (WGS) and acquired HiSeqX and HiSeq2500 in order to launch NGS services for research and clinical purposes. The clinical sequencing service is licensed in 49 states and two U.S. territories. In 2016, Macrogen Corp., Axeq Technologies, and Macrogen Clinical Lab consolidated under Macrogen Corp. The following year, Macrogen Corp. then became CAP-accredited.
Macrogen Corp. has partnered with researchers and clinicians in such institutions as Johns Hopkins University, the National Institutes of Health, Stanford University, and the University of Virginia. It has also collaborated with NRGene, a genomic data company. It has participated in large medical projects such as TOPMed, TEDDY project, Parkinson’s Disease project, and others.